Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211503 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL1009942 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL9875114 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL27274855 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL711369 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL18585071 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL5561948 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL713499 | 0.98 | TSHR (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL6263416 | 0.93 | TSHR (0.52) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL710282 | 0.93 | TSHR (0.52) | L3MBTL1TDP1TSHREPHX2TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739652-A1 | LIPIDS AND COMPOSITIONS THEREOF | Kernal Biologics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025134071-A1 | MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS | SANOFI (FR) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025010290-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023147545-A2 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20210300962-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2021159021-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-1141172-A1 | LIQUID CRYSTAL MATERIALS | QinetiQ Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000029505-A1 | LIQUID CRYSTAL MATERIALS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | L3MBTL1 3485/4885TDP1 1452/4885TSHR 1372/4885 |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | L3MBTL1 1375/4885TDP1 1941/4885TSHR 2195/4885 |
| US-20210300962-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | CYP21A2, CYP46A1, CYP17A1 | L3MBTL1 3700/4885TDP1 1706/4885TSHR 1457/4885 |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | L3MBTL1 3485/4885TDP1 1452/4885TSHR 1372/4885 |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | L3MBTL1 295/4885TDP1 1579/4885TSHR 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.